Drug Profile
Research programme: multiple sclerosis therapy - Acambis
Alternative Names: Multiple sclerosis therapy research programme - AcambisLatest Information Update: 01 Mar 2000
Price :
$50
*
At a glance
- Originator Acambis
- Developer Acambis; Multiple Sclerosis Society; University of Bristol
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 01 Mar 2000 Discontinued-Preclinical for Multiple sclerosis in United Kingdom (Intranasal)
- 05 Mar 1998 New profile
- 05 Mar 1998 Preclinical development for Multiple sclerosis in United Kingdom (Intranasal)